Treatment of Lower Extremity Spider Veins With Excel V

Inclusion Criteria

• Fitzpatrick Skin Type I - III
• Having at least 2 separate areas measuring 5cm x 5cm of lower extremity spider veins
• Having lower extremity spider veins less than 2.0mm in diameter, linear or branching, and red, pink, blue and/or purple in color, as assessed by the Investigator
• Having lower extremity spider veins appropriate for laser treatment, as assessed by the Investigator
• Subject must be able to read, understand and sign the Informed Consent Form
• Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions
• Wiling to have limited sun exposure for the duration of the study, including the follow-up period
• Willingness to have digital photographs taken of lower extremity spider veins
• Agree not to undergo any other procedure for the treatment of lower extremity spider veins during the study
• Willing to not take any 'prn' medications for aches and pains (such as Tylenol® or Advil®) on the days of the laser treatments
• For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study

Exclusion Criteria

• Having received any prior laser treatment for lower extremity spider veins
• Fitzpatrick Skin Type IV - VI
• Pregnant
• Having an infection, dermatitis or a rash in the treatment area
• Having significant varicosities or perforator veins
• History of keloid scarring, hypertrophic scarring or of abnormal wound healing
• History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications
• History of connective tissue disease, such as systemic lupus erythematosus or scleroderma
• History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation
• Having a known anticoagulative condition or taking anticoagulation medications
• History of thromboembolic disease, such as deep vein thrombosis (DVT)
• History of seizure disorders due to light
• Having a history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area, unless treatment is conducted following a prophylactic regimen
• Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely)
• Suffering from significant concurrent illness, such as insulin-dependent diabetes (type I or II), peripheral vascular disease or peripheral neuropathy
• Undergoing systemic chemotherapy for the treatment of cancer
• Systemic use of isotretinoin (Accutane®) within 6 months of study participation
• Any use of gold therapy for disorders such as rheumatologic disease or lupus
• Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study
• Participation in a study of another device or drug within three months prior to enrollment or during the study
• As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study